All In Biotech

NDA 201820 · Chiesi

Bethkis

Tobramycin · Inhalation · Aminoglycoside Antibacterial

Last checked: Nov 19, 2026Latest source record: Feb 10, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Oct 12, 2012

Approved uses

1

Original approval plus efficacy supplements

Registered trials

144

50 Phase 3, 6 recruiting

FAERS reports

14,537

11,256 serious, 1,372 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 24, 2023.

BETHKIS is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV 1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )] . BETHKIS is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in one second (FEV 1 ) less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia . ( 1 )

Mechanism: BETHKIS is an aminoglycoside antibacterial [see Clinical Pharmacology ( 12.4 )] .

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BETHKIS · TOBRAMYCIN 300MG/4ML · SOLUTION, INHALATION · Prescription · TE AN

Clinical trials

Interventional ClinicalTrials.gov studies with "Tobramycin" as an intervention, any sponsor and status, largest first.

All 144 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,324
  • pneumonia938
  • infective pulmonary exacerbation of cystic fibrosis784
  • dyspnoea759
  • drug ineffective700
  • acute kidney injury688
  • death575
  • hospitalisation550
  • cough534
  • cystic fibrosis515
  • condition aggravated508
  • infection491

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200480
200597
200677
2007124
200891
200999
2010101
2011208
2012189
2013165
2014273
2015536
2016696
2017762
20181,328
20192,040
20201,899
20211,145
20221,032
2023871
20241,090
2025947
2026687

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Bethkis* (Tobramycin*) · HCPCS J7682

2024 spending

$10.2M

Beneficiaries

3,533

10,777 claims

Per beneficiary

$2,874

2024 ASP limit $17.83 per unit

View as table
YearSpending
2020$19,304,300
2021$19,742,375
2022$14,068,878
2023$15,144,747
2024$10,153,227

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 791 on PubMed

Sponsor: Chiesi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.